Olivier M - Search Results

1

Recent advances in p53 research: an interdisciplinary perspective.

Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel CC, Hainaut P. Olivier M, et al. Cancer Gene Ther. 2009 Jan;16(1):1-12. doi: 10.1038/cgt.2008.69. Epub 2008 Sep 19. Cancer Gene Ther. 2009. PMID: 18802452 Review.

2

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Petitjean A, et al. Among authors: olivier m. Hum Mutat. 2007 Jun;28(6):622-9. doi: 10.1002/humu.20495. Hum Mutat. 2007. PMID: 17311302

3

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.

Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. Petitjean A, et al. Among authors: olivier m. Oncogene. 2007 Apr 2;26(15):2157-65. doi: 10.1038/sj.onc.1210302. Oncogene. 2007. PMID: 17401424 Review.

4

Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies.

Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Goldstein I, et al. Among authors: olivier m. Cancer Gene Ther. 2011 Jan;18(1):2-11. doi: 10.1038/cgt.2010.63. Epub 2010 Oct 22. Cancer Gene Ther. 2011. PMID: 20966976 Review.

5

Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. Olivier M, et al. Cancer Res. 2003 Oct 15;63(20):6643-50. Cancer Res. 2003. PMID: 14583457

6

The tumor suppressor gene TP53: implications for cancer management and therapy.

Seemann S, Maurici D, Olivier M, Caron de Fromentel C, Hainaut P. Seemann S, et al. Among authors: olivier m. Crit Rev Clin Lab Sci. 2004;41(5-6):551-83. doi: 10.1080/10408360490504952. Crit Rev Clin Lab Sci. 2004. PMID: 15603511 Review.

7

Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.

Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. Mathe E, et al. Among authors: olivier m. Nucleic Acids Res. 2006 Mar 6;34(5):1317-25. doi: 10.1093/nar/gkj518. Print 2006. Nucleic Acids Res. 2006. PMID: 16522644 Free PMC article.

8

Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.

Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P. Palmero EI, et al. Among authors: olivier m. Curr Opin Oncol. 2010 Jan;22(1):64-9. doi: 10.1097/CCO.0b013e328333bf00. Curr Opin Oncol. 2010. PMID: 19952748 Review.

9

TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier M, Hollstein M, Hainaut P. Olivier M, et al. Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008. doi: 10.1101/cshperspect.a001008. Cold Spring Harb Perspect Biol. 2010. PMID: 20182602 Free PMC article. Review.

10

Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines.

Fernández-Cuesta L, Anaganti S, Hainaut P, Olivier M. Fernández-Cuesta L, et al. Among authors: olivier m. Breast Cancer Res Treat. 2011 Jan;125(1):35-42. doi: 10.1007/s10549-010-0819-x. Epub 2010 Mar 11. Breast Cancer Res Treat. 2011. PMID: 20221692

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

693 results

Search Page

Filters